Cyclosporine A is a new and potent immunosuppressant with high specificity and is widely used in controlling a variety of immunological rejection after organ transplantation. Research found that cyclosporine A suppresses the immune rejection in moderate to severe dry eye syndrome treatment. For mooren ulcers and autoimmune eye diseases, it has a significant effect. The application progress of Cyclosporine A in clinical ophthalmology is now reviewed
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Dry eye disease (DED) is the most frequent encountered ocular surface condition and remains one of t...
Purpose To study the effect of Cyclosporine A (CsA) on immune-mediated canine keratoconjunctivitis s...
To review the current treatment of chronic dry eye syndrome, focusing on cyclosporine A (CsA), a sys...
Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and acti...
George D Kymionis, Dimitrios I Bouzoukis, Vassilios F Diakonis, Charalambos SiganosDepartment of Oph...
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of...
Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular...
Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by d...
Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cel...
Cyclosporine A (CsA) is a neutral lipophilic compound that was first isolated in the 1970s from the ...
Cyclosporine A (CsA) has been in clinical use for some decades, primarily for the prevention and tre...
Cyclosporine (CsA) therapy has evolved considerably since its introduction as the primary immunosupp...
International audienceBackground: Cyclosporine A (CsA) has been used as a topical treatment for vari...
Cyclosporine A (CsA) has been demonstrated to be effective for the treatment of a variety of ophthal...
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Dry eye disease (DED) is the most frequent encountered ocular surface condition and remains one of t...
Purpose To study the effect of Cyclosporine A (CsA) on immune-mediated canine keratoconjunctivitis s...
To review the current treatment of chronic dry eye syndrome, focusing on cyclosporine A (CsA), a sys...
Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and acti...
George D Kymionis, Dimitrios I Bouzoukis, Vassilios F Diakonis, Charalambos SiganosDepartment of Oph...
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of...
Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular...
Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by d...
Cyclosporine A, an inhibitor of calcineurin, exerts an immunomodulator action interfering with T cel...
Cyclosporine A (CsA) is a neutral lipophilic compound that was first isolated in the 1970s from the ...
Cyclosporine A (CsA) has been in clinical use for some decades, primarily for the prevention and tre...
Cyclosporine (CsA) therapy has evolved considerably since its introduction as the primary immunosupp...
International audienceBackground: Cyclosporine A (CsA) has been used as a topical treatment for vari...
Cyclosporine A (CsA) has been demonstrated to be effective for the treatment of a variety of ophthal...
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Dry eye disease (DED) is the most frequent encountered ocular surface condition and remains one of t...
Purpose To study the effect of Cyclosporine A (CsA) on immune-mediated canine keratoconjunctivitis s...